November 29, 2019
San Diego, CA – Aardvark Therapeutics, Inc., a company focused on developing novel small molecule therapeutics for obesity and metabolic diseases, today announced the successful completion of the second tranche of a $15 million Series A financing. The financing was co-led by Vickers Venture Partners and Premier Partners, with participation from BNH Investment, Korea Omega, and other investors.
Vickers vice-chairman Jeffrey Chi, along with Premier Partners managing director Bob Shin, have joined Aardvark’s board of directors.
The funds raised will be deployed to complete IND-enabling studies towards an IND filing and first-in-human clinical trial in 2020. In addition, the company plans on developing its proprietary compounds for multiple therapeutic indications including obesity, hyperlipidemia, rare metabolic diseases, and others.
About Vickers Venture Partners:
Vickers Venture Partners is a venture capital firm focused on early-stage investments in Asia and beyond. The firm’s portfolio covers life sciences, technology, media, and telecommunications as well as consumer and financial services. Some of its partners have track records that include hits such as Baidu.com, Inc (NASDAQ: BIDU), Focus Media Holding Ltd (NASDAQ: FMCN), Kongzhong Corp (NASDAQ: KONG), Cambridge Real Estate Investment Trust (SGX: CREIT), Sunfun Info Co. (Gretai: 5278) Asian Food Channel (trade sale), UUCUN (trade sale), TWG Tea (trade sale), RTG Asia (trade sale), JJE (trade sale), Hillstone (trade sale), M-Daq (trade sale), Tenfen (trade sale), Kuyun (trade sale) and Mainspring (trade sale). The total market value of the companies that the partners have helped grow exceeds US$90 billion today.
Vickers Venture Partners was founded by Finian Tan, Khalil Binebine, Jeffrey Chi, Damian Tan, and Linda Li in 2005. It is based in Singapore with offices in Kuala Lumpur, Shanghai, Hong Kong, London, New York, San Diego, and San Francisco.
About Premier Partners:
Founded in 2005 in South Korea, Premier Partners has invested in more than 110 companies, and achieved successful investment results through IPOs or M&A. Premier is composed of PE, VC and Bio divisions which are led by five partners with over 19 years of investment experience on average, including two co-founders who have worked together since 1997. Each partner has diverse industry & investment experience and a proven track record, which enables rapid and efficient investment decisions. Premier has managed nine funds including four PE funds with KRW 772 billion AUM, four VC funds with KRW 178 billion AUM and one BIO fund with KRW 75 billion for institutional and private investors.
About Aardvark Therapeutics, Inc.:
Aardvark Therapeutics is a biotechnology company focused on the development of novel small molecules for obesity, metabolic diseases, and other indications.